# US 2022/0033380 A1 · Poly-adp ribose polymerase (parp) inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033380 A1
- Document ID: US20220033380A1
- Status: Published application
- Kind: A1
- Application number: 17/342,873
- Filed: 2021-06-09
- Published: 2022-02-03
- Earliest claimed: 2016-12-30
- Assignees: Mitobridge, Inc.
- Applicants: Mitobridge, Inc.
- Inventors: Taisuke Takahashi; Arthur Kluge; Bharat Lagu; Nan Ji
- Web page: https://patentgrep.com/patent/US20220033380A1

## CPC

- C07D 239/74: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
- C07D 401/14: containing three or more hetero rings
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 13/12: of the kidneys
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 35/00: Antineoplastic agents
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/08: linked by a carbon chain containing alicyclic rings
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/08: linked by a carbon chain containing alicyclic rings
- C07D 403/14: containing three or more hetero rings
- C07D 405/10: linked by a carbon chain containing aromatic rings
- C07D 405/14: containing three or more hetero rings
- C07D 417/08: linked by a carbon chain containing alicyclic rings
- C07D 417/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 495/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is related to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula: The present invention is also related a method of treating a subject with a disease which can be ameliorated by inhibition of poly(ADP-ribose)polymerase (PARP). The definitions of the variables are provided herein.

## Claims

### Claim at position 1

-27. (canceled)

### Claim 28

A method of treating a subject with pancreatitis, comprising administering to the subject an effective amount of a compound, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier; and wherein said compound is 6-[(3S)-4-[3-(6-fluoro-4-oxo-3H-quinazolin-2-yl)propanoyl]-3-methyl-piperazin-1-yl]pyridine-3-carbonitrile.

### Claim 29 (depends on 28)

The method of claim 28, wherein said compound, said pharmaceutically acceptable salt thereof, or said pharmaceutical composition is administered orally.

### Claim 30

A method of treating a subject with pancreatitis, comprising administering to the subject an effective amount of a compound, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier; and wherein said compound is 6-[(3S)-4-[3-(5-fluoro-4-oxo-3H-quinazolin-2-yl)propanoyl]-3-methyl-piperazin-1-yl]pyridine-3-carbonitrile.

### Claim 31 (depends on 30)

The method of claim 30, wherein said compound, said pharmaceutically acceptable salt thereof, or said pharmaceutical composition is administered orally.

### Claim 32

A method of treating a subject after surgery, comprising administering to the subject an effective amount of a compound, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier; and wherein said compound is 6-[(3S)-4-[3-(6-fluoro-4-oxo-3H-quinazolin-2-yl)propanoyl]-3-methyl-piperazin-1-yl]pyridine-3-carbonitrile or 6-[(3S)-4-[3-(5-fluoro-4-oxo-3H-quinazolin-2-yl)propanoyl]-3-methyl-piperazin-1-yl]pyridine-3-carbonitrile.

### Claim 33 (depends on 32)

The method of claim 32, wherein said compound, said pharmaceutically acceptable salt thereof, or said pharmaceutical composition is administered orally
